Deal of the Day — limited-time pharmacy picks!
Femistra 1mg Tablet

Femistra 1mg Tablet

Prescription requiredRx Required

Salt Composition: Anastrozole

Expiry Date: 01/2028

Special offer

Buy at $13.34

$13.34

Inclusive of all taxes

▼

10 tablet

About The Product

Breast Cancer

Femistra 1mg tablet is a hormone therapy medication that is used to treat breast cancer in postmenopausal women. Anastrozole is the generic name of this medication, and it is a competitive non-steroidal aromatase inhibitor. This medication is strictly prescription-based. Femistra tablet can be used with other possible treatment options like radiation, surgery, etc, or can be taken alone. Advanced breast cancer that has spread to different areas of the body or within the breast can also be cured with the Femistra tablet.

Uses

Breast cancer

Side Effects

Most side effects of Femistra 1mg Tablet do not require medical attention as they may disappear as your body adjusts to the medicine.

In case these side effects become worse, consult your doctor immediately.

  • Constipation
  • Diarrhea
  • Weight gain, Heartburn Loss of appetite
  • Hair thinning
  • Tingling of hands and feet
  • Trouble sleeping
  • Dizziness
  • Chest pain
  • Swelling of hands
  • Yellowing of skin and eyes
  • Vision complications
  • Vaginal bleeding

How To Use

  • The doctor prescribes this medicine; hence, it is advisable to follow the prescription.
  • Femistra tablets are taken orally once a day, and they can be taken with or without food as advised by the doctor.
  • Femistra tablet should be taken at the same time every day for maximum benefits.
  • Contact your doctor or any healthcare provider in case of an overdose and seek medical attention immediately.

How It Works

In many breast cancers, estrogen stimulates the uncontrollable growth of cancerous cells. Aromatase enzyme, present mainly in the adrenal glands can convert the androgens to estrogen, and this estrogen furthermore influences the cancerous cells.

Thus, Femistra is a non-steroidal inhibitor that competitively binds to the aromatase enzyme and stops the production of estrogen. As a result, it inhibits the growth and spreading of the tumor cells.

Safety Advice

Alcohol
It is advisable not to consume alcohol while taking the Femistra tablet. It is suggested that to consult your doctor.
Pregnancy
Do not take the Femistra tablet without consulting a doctor in case of pregnancy. Femistra tablet is considered not safe to use in case of pregnancy as it may harm the developing baby, according to research evidence.
Breast Feeding
Without a doctor's consultation, do not take this medicine if you're breastfeeding. Femistra tablet may cause toxicity to the developing baby as it may be transferred through the milk of the mother, so it's not considered safe to use Femistra tablet during breastfeeding.
Driving
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine. Femistra Tablet can make you feel sleepy, affect your vision, alertness may be reduced. It is advised not to drive if these symptoms exist while taking Femistra Tablet.
Kidney
Do not take the Femistra 1mg tablet without a doctor's consultation in case of kidney problems. Patients with severe kidney disease should use Femistra Tablet with caution, and the patient may require an adjustment in dose as recommended by the doctor. A Regular kidney test should be done to monitor the side effects of Femistra Tablet on the kidneys.
Liver
Share your medical history with the doctor in case of liver disease before taking this medicine. Patients with severe Liver disease should use Femistra Tablet with caution, and the patient may require an adjustment in dose as recommended by the doctor. A Regular liver test should be done to monitor the side effects of Femistra Tablet on the liver.

Missed Doses

  • If you forget to take a dose of Femistra 1mg tablet consult your doctor.
  • Don’t double up the next dose to cope with the missed one unless your doctor recommends it. ​

FAQs

​ Femistra is an anticancer tablet that is primarily used in the treatment of breast cancer.

​

Reference

  1. Miller, W. R., Bartlett, J., Brodie, A. M., et al. (2020). Aromatase inhibitors: Are there differences between steroidal and nonsteroidal aromatase inhibitors, and do they matter? The Oncologist, 13(8), 829–837 - https://silice.csic.es/publication/2f55f7a9-252c-4d4b-bf88-950931448c35
  2. Anderson, W. F., Chatterjee, N., Ershler, W. B., et al. (2022). Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Research and Treatment, 76(1), 27–36 - https://pubmed.ncbi.nlm.nih.gov/12408373/
  3. Miller, W., Stuart, M., Sahmoud, T., et al. (2023). Anastrozole (‘Arimidex’) blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer. British Journal of Cancer, 87(9), 950–955 - https://pubmed.ncbi.nlm.nih.gov/12434282/
  4. Yang, Y., Pan, W., Tang, X., Wu, S., & Sun, X. (2025). A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer. Oncotarget, 8(29), 48362–48374 - https://pmc.ncbi.nlm.nih.gov/articles/PMC5564654/
  5. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies, C., Godwin, J., et al. (2021). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. The Lancet, 378(9793), 771–784 - https://pubmed.ncbi.nlm.nih.gov/21802721/
  6. Ingle, J. N., Suman, V. J., Ma, C. X., et al. (2025). Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. Steroids, 99(Pt A), 32–38 - https://pmc.ncbi.nlm.nih.gov/articles/PMC4339673/
  7. Cairns, J., Ingle, J. N., Liu, M. C., et al. (2023). The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1. Breast Cancer Research, 21(1), 47 - https://pmc.ncbi.nlm.nih.gov/articles/PMC6448248/
  8. Tang, M. R., Wang, Y. X., Guo, S., Han, S. Y., & Wang, D. (2022). CSMD1 exhibits antitumor activity in A375 melanoma cells through activation of the Smad pathway. Apoptosis, 17(9), 927 - https://pubmed.ncbi.nlm.nih.gov/22538441/

Certified Content

Written By
Venika Choudhary

Venika Choudhary

Medical Content Writer @ Magicine Pharma

Reviewed By
Dr. Aditya Sarin

Dr. Aditya Sarin

MBBS, MD - General Medicine, DrNB - Medical Oncology | 11 Years Experience

Check Our Editorial Policy

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026